Naptumomab Estafenatox

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Naptumomab Estafenatox
Accession Number
DB12807
Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Other protein based therapies
Description

Naptumomab Estafenatox has been used in trials studying the treatment of Pancreatic Cancer, Renal Cell Carcinoma, and Non-Small-Cell Lung Carcinoma.

Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
Not Available
External IDs
ABR-217620
Categories
UNII
93T929W6LC
CAS number
676258-98-3

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Naptumomab Estafenatox.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Naptumomab Estafenatox.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Naptumomab Estafenatox.
Anthrax immune globulin humanThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Naptumomab Estafenatox.
Antithymocyte immunoglobulin (rabbit)The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Naptumomab Estafenatox.
Bacillus calmette-guerin substrain connaught live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Naptumomab Estafenatox.
Bacillus calmette-guerin substrain tice live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Naptumomab Estafenatox.
BasiliximabThe risk or severity of adverse effects can be increased when Basiliximab is combined with Naptumomab Estafenatox.
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Naptumomab Estafenatox.
BevacizumabThe risk or severity of adverse effects can be increased when Bevacizumab is combined with Naptumomab Estafenatox.
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347911384

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
1CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Malignant Neoplasm of Pancreas / Renal Cell Adenocarcinoma1
2, 3CompletedTreatmentRenal Cell Adenocarcinoma1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Drug created on October 20, 2016 18:23 / Updated on October 01, 2018 15:20